To maintain best practices, the Antimicrobial Stewardship Committee and Microbiology have decided to suppress susceptible ceftriaxone results for Enterobacter cloacae. Ceftriaxone should not be used to treat this organism due to high probability of inducing AmpC beta lactamase that may result in treatment failure. Additionally, piperacillin/tazobactam and amoxicillin/clavulanate susceptible results will be suppressed for all Extended Spectrum Beta Lactamase (ESBL) producing isolates as outcome data suggests higher mortality when these are utilized in the treatment of ESBL producing isolates.